A new chapter in weight management has arrived.

 

Wegovy pill is now available, bringing GLP-1 weight-loss science to a once-daily pill for the first time and expanding treatment options for more than 100 million Americans living with obesity.

 

Approved on December 22, 2025, Wegovy pill is indicated for use alongside a reduced-calorie diet and increased physical activity for adults with obesity, or adults who are overweight with at least one weight-related medical condition. 

 

The approval introduces a needle-free alternative to injectable GLP-1 therapies, long considered a barrier for some patients seeking treatment.

 

“We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy in a once-daily pill that demonstrated about 17% weight loss, if all patients stayed on treatment,” said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. 

 

“Wegovy pill is here, and it represents a significant innovation as the first and only GLP-1 pill for weight loss. This moment is about changing what's possible in weight management, and to make that possible, we have worked to ensure Wegovy pill is affordable and accessible to those who need it, however they choose to receive their care.”

 

The pill builds on the success of Wegovy (semaglutide) injection 2.4 mg, which has been prescribed to millions since its 2021 approval. 

 

In phase 3 trials, Wegovy pill delivered weight-loss results unmatched by other oral GLP-1 obesity candidates, achieving an average weight loss of 16.6% when used with diet and exercise and when all patients remained on treatment, compared with 2.7% for placebo. Even when accounting for patients who did not stay on treatment, average weight loss reached 13.6%, far exceeding the 2.4% seen with placebo.

 

With its once-daily oral dosing, Wegovy

pill offers a new, practical option designed to fit into everyday routines, giving patients another pathway to achieve meaningful and sustained weight loss.